-
公开(公告)号：US20120321616A1
公开(公告)日：2012-12-20
申请号：US13481640
申请日：2012-05-25
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
公开(公告)号：US20110027272A1
公开(公告)日：2011-02-03
申请号：US12817097
申请日：2010-06-16
IPC分类号： A61K39/395 , A61P37/04 , A61P31/12
CPC分类号： C07K16/1027 , A61K9/0019 , A61K9/0043 , A61K39/39591 , A61K39/42 , A61K47/183 , A61K47/22 , A61K47/26 , A61K2039/505 , A61K2039/54 , C07K16/00 , C07K2317/24 , C07K2317/565 , C07K2317/94
摘要： The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
摘要翻译： 本发明提供了免疫特异性结合呼吸道合胞病毒（RSV）抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂表现出稳定性，低至不可检测的聚集水平，并且极少数或不损失生物 SYNAGIS®或其抗原结合片段的活性，甚至在长时间的储存期间。 特别地，本发明提供了免疫特异性结合RSV抗原的SYNAGIS或其抗原结合片段的液体制剂，该制剂基本上不含表面活性剂，无机盐和/或其它常见的赋形剂。 此外，本发明提供使用本发明的液体制剂预防，治疗或改善与RSV感染相关的症状的方法。
-
搜索结果
2 条记录 (耗时 0.05 秒)
